Background The 2025 American College of Cardiology/American Heart Association guidelines endorse de-escalation to ticagrelor monotherapy after percutaneous coronary intervention (PCI) for acute coronary syndromes (ACSs), whereas the 2023 European Society of Cardiology guidelines recommend 12-month dual antiplatelet the...
Michele Maremmani, Enrico Citerni, O. de Filippo et al.· JACC: Advances· 0 citations
Elderly patients were at higher risk of NACE, driven by an increased risk of both ischemic and bleeding events, the latter including access-site and nonaccess-site hemorrhages of both minor and major severity.
S. Benenati, F. Gragnano, Sebastiano Stratoti et al.· Journal of Cardiovascular Me...· 1 citation
In patients with acute MI undergoing PCI, first-line evolocumab combined with high-intensity lipid-lowering therapy produced rapid and sustained LDL-C reduction, with more than 80% of patients reaching the guideline-recommended target at 1 year.
G. Montalescot, E. Ferrari, G. Souteyrand et al.· Journal of the American Medi...· 3 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.